Acer Therapeutics Performance
| ACERDelisted Stock | USD 0.81 0.10 14.08% |
The firm shows a Beta (market volatility) of 1.34, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acer Therapeutics will likely underperform. Acer Therapeutics right now shows a risk of 0.0%. Please confirm Acer Therapeutics potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Acer Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acer Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical and fundamental indicators, Acer Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 12.7 M |
Acer |
Acer Therapeutics Relative Risk vs. Return Landscape
If you would invest 81.00 in Acer Therapeutics on January 24, 2024 and sell it today you would earn a total of 0.00 from holding Acer Therapeutics or generate 0.0% return on investment over 90 days. Acer Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Acer, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acer Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acer Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acer Therapeutics, and traders can use it to determine the average amount a Acer Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ACER |
Based on monthly moving average Acer Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acer Therapeutics by adding Acer Therapeutics to a well-diversified portfolio.
Acer Therapeutics Fundamentals Growth
Acer Stock prices reflect investors' perceptions of the future prospects and financial health of Acer Therapeutics, and Acer Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acer Stock performance.
| Return On Equity | -4.73 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 52.01 M | |||
| Shares Outstanding | 24.46 M | |||
| Price To Earning | (7.40) X | |||
| Price To Book | 17.26 X | |||
| Price To Sales | 174.52 X | |||
| EBITDA | (24.81 M) | |||
| Cash And Equivalents | 14.47 M | |||
| Cash Per Share | 0.91 X | |||
| Total Debt | 11.86 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (30.25 M) | |||
| Earnings Per Share | (1.98) X | |||
| Total Asset | 11.62 M | |||
| Retained Earnings | (140.75 M) | |||
| Current Asset | 6.61 M | |||
| Current Liabilities | 5.62 M | |||
About Acer Therapeutics Performance
To evaluate Acer Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Acer Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Acer Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Acer Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Acer's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. Acer Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Things to note about Acer Therapeutics performance evaluation
Checking the ongoing alerts about Acer Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acer Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acer Therapeutics is not yet fully synchronised with the market data | |
| Acer Therapeutics has some characteristics of a very speculative penny stock | |
| Acer Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 11.86 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Acer Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acer Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Acer Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acer Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acer to invest in growth at high rates of return. When we think about Acer Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.24 M) with profit before overhead, payroll, taxes, and interest of 1.26 M. | |
| Acer Therapeutics currently holds about 14.47 M in cash with (30.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of Acer Therapeutics shares are held by company insiders |
- Analyzing Acer Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acer Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Acer Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acer Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acer Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acer Therapeutics' stock. These opinions can provide insight into Acer Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Acer Therapeutics information on this page should be used as a complementary analysis to other Acer Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |